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ABSTRACT
The objectives of this study were to prepare microcapsules containing verapamil and propranolol and to evaluate 
the kinetics and mechanism of drug release from the microcapsules using USP Apparatus 1. The effects of polymer 
concentration and polymer type on the cumulative amount of drug released were evaluated. The microcapsules were 
manufactured using Eudragit RS and RL polymers by solvent evaporation with the ultimate aim of prolonging drug 
release. Twenty-four formulations were prepared using different drug/polymer ratios. The effects of polymer type and 
polymer/drug ratios on the size, flow properties, surface morphology, and the release characteristics of the microcapsules 
were examined. The effects of drug inclusion methods on drug loading, encapsulation efficiency, and release properties 
of the complex microcapsules were also investigated. The formulations containing drug/polymer ratio 1:4 (w/w) were 
the most appropriate with respect to encapsulation efficiency (70%), flow properties (HR = 1.2), drug loading (15–20%), 
and drug release characteristics, in all cases. The release kinetics from the different formulations followed mainly a 
diffusion-controlled mechanism. 
INTRODUCTION
Microencapsulation is defined as the application of a thin coating to individual core materials that have an arbitrary particle size range between 5 
and 5000 µm (1, 2). Microencapsulation is widely used in 
the pharmaceutical and other sciences to mask tastes or 
odors, prolong release, impart stability to drug molecules, 
improve bioavailability, and as multi-particulate dosage 
forms to produce controlled or targeted drug delivery 
(3–6). It is therefore a rapidly expanding technology for 
achieving sustained-release dosage forms.
The solvent-evaporation method of microencapsulation 
involves the use of emulsification of a solution containing 
polymer and drug with an additional medium in which 
the drug and polymer cannot dissolve (7). The technique 
is relatively simple and has been used to prepare 
microcapsules of a variety of compounds using several 
different polymeric materials (5, 8).
There are several formulation and process parameters 
that, when modified during the manufacture of microcap-
sules by solvent evaporation, may affect the properties 
of microspheres. The parameters in question include the 
aqueous solubility of raw material or drug to be encapsu-
lated, the type and concentration of the dispersing agent, 
the polymer/drug ratio, and the stirring rate used to 
agitate the emulsion system formed during the manufac-
turing process (7). The Eudragit range of products is a 
series of acrylic and methacrylic acid copolymers that are 
available in several different ionic forms. Eudragit RL and 
RS grades of polymer are insoluble in aqueous media 
but are permeable and have the ability to produce 
pH-independent drug-release profiles. The permeability of 
Eudragit RS and RL polymers in aqueous media is a 
consequence of the presence of quaternary ammonium 
functional groups in their molecular structures, and the 
greater prevalence of these functionalities in the RL grade 
results in it being more permeable than the RS grade (9).
We focused considerable attention on the dissolution 
testing of the microcapsules manufactured in these 
studies, since in vitro dissolution testing of solid oral 
dosage forms is an integral part of pharmaceutical 
development and routine quality control monitoring of 
drug release characteristics (10). The USP recommends 
seven different types of apparatus for in vitro release 
testing. USP Apparatus 1 (basket) and 2 (paddle) were 
designed for the evaluation of immediate-release (IR) and 
modified-release (MR) oral formulations (11), whereas 
USP Apparatus 5 (paddle over disc), 6 (cylinder), and 7 
(reciprocating holder) were designed for the assessment 
of transdermal products. USP Apparatus 3 (reciprocating 
cylinder) and 4 (flow-through cell) were designed for the 
evaluation of extended-release (ER) oral formulations (12).
In these studies, propranolol hydrochloride (PHCl) and 
verapamil hydrochloride (VHCl) were used to evaluate the 
potential of the solvent-evaporation microencapsulation 
technique to encapsulate drugs of different solubility and 
permeability. Although the solvent-evaporation process 
is a relatively simple concept, many process variables 
may influence the formation and properties of the 
microcapsules that are produced. 1Corresponding author.
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The Biopharmaceutics Classification System (BCS) 
recommends methods for classifying oral drugs into four 
different categories based on their aqueous solubility and 
intestinal permeability (13). VHCl, a calcium channel 
blocker, is widely used in the management of angina, 
supraventricular arrhythmias, and hypertension (14). 
PHCl is a non-selective, beta-adrenergic blocker that is 
used in the treatment of hypertension, angina pectoris, 
pheochromocytoma, and cardiac arrhythmias (15). VHCl 
and PHCl are BCS Class I drugs. Class I drugs are well 
absorbed and are readily soluble, and the rate-limiting 
step for absorption of these compounds is dissolution rate 
or gastric emptying rate should the dissolution rate be 
rapid (16). Reports of the preparation and evaluation of 
microcapsules manufactured using the selected drug 
candidates have been published (17–22); however, none 
have focused on a comparison of the resultant products.
The objectives of these studies were to incorporate 
two weakly basic, freely soluble drugs into matrix 
microcapsules and to investigate process parameters that 
affect the properties and in vitro dissolution of the drugs 
from microcapsules.
EXPERIMENTAL 
Preparation of Microcapsules
PHCl and VHCl microspheres were prepared by a 
solvent-evaporation method using different quantities of 
Eudragit RS and Eudragit RL polymers. Approximately 0.5, 
1.0, 1.5, 2.0, 2.5, and 3.0 g were accurately weighed and 
dissolved in 13.5 mL of acetone with stirring. A 500-mg 
quantity of the relevant drug and 50 mg of magnesium 
stearate were then dispersed in the polymer solution. The 
resultant milky white dispersion was poured into a vessel 
containing a mixture of 135 mL of liquid paraffin and 
15 mL of n-hexane and stirred for 5 h using a homogenizer 
fitted with a four-blade “butterfly” propeller with a 
diameter of 50 mm (Virtis Company, USA). Stirring was 
continued for 3 h at 500 rpm or until the acetone was 
completely evaporated. The manufacturing procedure is 
schematically represented in Figure 1.
Following removal of the acetone, the resultant micro-
capsules were harvested by vacuum filtration after which 
they were washed four times with 25 mL of n-hexane and 
dried at room temperature (25 °C) for 24 h.
Twenty-four batches of microcapsules with drug/
polymer ratios of 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6 (w/w) were 
prepared using Eudragit RS and RL as the encapsulation 
polymers. 
Size Distribution of Microcapsules
Once dried, the microcapsules were sized by passing 
through a nest of standard sieves of mesh sizes #18 
(850 µm), 24 (710 µm), and 80 (177 µm). The mean particle 
size of each fraction was taken as the arithmetic mean size 
of the apertures of the preceding screen on which the 
particles had been retained.
Flow Properties of Microcapsules
The Hausner ratio of the microcapsules manufactured 
using different formulations was computed according to 
the following relationship (23)
HR =
tap
bulk
r
r
where rtap is tapped density and rbulk is bulk density.
Scanning Electron Microscopy 
The shape and surface morphology of the microcapsules 
were investigated using scanning electron microscopy 
(Tescan, VEGA LMU, Czech Republic). The microcapsules 
were mounted onto a double-sided carbon stub that was 
placed on a sample disc carrier (3-mm height, 10-mm 
diameter) and sputter coated (Balzers Union Ltd, Balzers, 
Lichtenstein) with gold under vacuum (0.25 Torr). The 
samples were then monitored, and an image was 
generated using a 20 kV electron beam.
In Vitro Release Studies
The USP basket apparatus has been used to study in 
vitro drug release from microspheres (24). The dissolution 
rate of the different drugs from the microspheres was 
studied in a pH 7.4 phosphate buffer solution (100 mM). A 
USP Apparatus 1 (rotating basket) set to sink conditions 
with the basket at 100 rpm was used to generate drug 
release profiles. Accurately weighed samples of the 
microspheres were placed in the baskets and then 
lowered into the dissolution medium that was maintained 
at 37 ± 0.5 °C. Each formulation was tested in triplicate. 
Sample aliquots were withdrawn at 0, 0.5, 1, 2, 4, 8, and 
12 h and were filtered through a 0.45-µm filter before 
analysis by HPLC. A volume of dissolution medium equal 
to what had been removed for analysis was replaced to 
maintain constant volume. Samples for analysis were 
monitored spectrophotometrically (UV-Mini 1240, UV-vis 
Figure 1. Manufacturing procedure used to produce microcapsules for these 
studies.
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Spectrophotometer, Shimadzu Corporation, Japan) by 
recording the absorbance at 278 nm for VHCl and 280 nm 
for PHCl. All products were observed visually to assess 
whether any physical changes to the particles occurred 
during the dissolution testing process. 
Experimental results were expressed as mean ± SD. 
Student’s t-test and one-way analysis of variance (ANOVA) 
were applied to check significant differences in drug 
release from different formulations. Differences were 
considered to be statistically significant at p < 0.05. The 
statistical software used for analysis was GraphPad Prism 
Software Version 4.0 (GraphPad Prism Software, San Diego, 
CA, USA). 
Drug Release Kinetics
To investigate the mechanism of drug release from 
the microcapsules, the release data were analyzed using 
zero-order kinetic (25), Higuchi (26, 27), Korsmeyer–Peppas 
(28), Kopcha (29), and Makoid–Banakar (30) models. 
Modeling was performed using GraphPad Prism Software 
Version 4.0 (GraphPad Prism Software, San Diego, CA, USA). 
The software estimates the parameters of a nonlinear 
function that provides the closest fit between experimen-
tal observations and the non-linear function. The mathe-
matical expressions that describe the models used to 
describe the dissolution curves in these studies are 
summarized in Table 1. The best-fit solution was identified 
by evaluating the coefficient of determination (R2), where 
the highest R2 value indicates the best fit. 
Determination of Drug Loading, Encapsulation 
Efficiency, and Microcapsule Yield
The average drug content was determined by extraction 
of a 20-mg sample of microcapsules with methanol. 
Following filtration and appropriate dilution with additional 
methanol, the resultant concentration was determined 
using UV spectrophotometry, and the percent drug 
loading was calculated using the following equation:
% 100 Loading
weight of  drug
weight of  microparticles
= ×
The encapsulation efficiency of the process was 
calculated using the following equation:
Encapsulation Efficiency =
actual drug content
theoretical drug content
×100
The percentage yield of the microcapsules was determined 
for each drug candidate and was calculated using the 
following equation (31):
Yield =
M
Mo
% 100×
where M is the weight of microcapsules and Mo is the total 
expected weight of drug and polymer.
Assay Procedure
The total drug content of the microcapsules was 
determined by dissolving accurately weighed portions of 
each batch of microcapsules in 100 mL methanol and then 
monitoring the UV absorbance at the relevant wavelength 
for each compound. At the outset, calibration curves for 
the two drugs were constructed, and the correlation 
coefficients, r, of the curves were established. Furthermore, 
the polymers did not interfere with the assay, and all 
samples were assayed in triplicate. 
RESULTS AND DISCUSSION
During processing, it was observed that stirrer speeds of 
less than 500 rpm were not sufficient to produce micro-
capsules, and a huge coalesced mass was obtained. This is 
due in part to inadequate agitation of the media to 
disperse the inner phase in discreet droplets within the 
bulk phase. At stirring speeds above 1000 rpm, the 
turbulence caused frothing and adhesion of the micropar-
ticles to the container walls and propeller blade surfaces, 
resulting in high shear and a smaller size of the dispersed 
droplets. Spherical microspheres were obtained at a 
stirring rate of 500 rpm; therefore, this speed was used 
during manufacture of all microcapsules.
The use of magnesium stearate as a dispersion agent 
decreased the interfacial tension between the lipophilic 
and hydrophilic phases of the emulsion and further 
simplified the formation of microcapsules. As the solvent 
evaporated, the viscosity of the individual droplets 
increased, and highly viscous droplets were observed to 
coalesce at a faster rate than they could be separated. 
Magnesium stearate formed a thin film around the 
droplets and thereby reduced the extent of coalescence, 
before hardening of the capsules, on collision of the 
droplets. The resultant microcapsules were free-flowing, 
and the use of magnesium stearate was deemed effective.
When 1:1 (w/w) drug/polymer concentrations were 
used for both the Eudragit RS and RL polymers, the quality 
of microcapsules formed was poor (Figures 2 and 3). These 
were irregularly shaped, not flowing, and presented with 
lots of indentation. Microcapsules were only formed when 
Table 1. Mathematical Representation of Models Used to 
Describe the Release Profiles from the Microcapsules
Model Equation
Zero-order Qt = Qo + Kot
Higuchi Qt = Qo + KHt1/2
Korsmeyer–Peppas Qt = KKP tn
Kopcha Qt = At1/2 + Bt
Makoid–Banakar Qt = KMB tne(−ct)
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the polymer concentration was increased to ratios of 
between 1:2 and 1:6 (w/w) with respect to the drug 
concentration. 
Discrete, spherical, and uniform microcapsules were 
obtained with a 1:4 (w/w) drug/polymer ratio for both the 
RS and RL polymers, as can be seen in Figures 4–7. It is also 
evident that the microcapsules exhibited slightly porous 
surfaces, probably due to the high concentration of drug 
in the microcapsules. 
SEM was performed to determine whether microcapsules 
had been formed. The use of SEM is important for estab-
lishing the encapsulating ability of different polymers, 
since the degree of porosity may be observed, and 
therefore, encapsulation ability of the polymers can be 
Figure 2. SEM of a PHCl/ Eudragit RS 1:1 (w/w) microcapsule.
Figure 3. SEM of a VHCl/ Eudragit RS 1:1 (w/w) microcapsule.
Figure 4. SEM of a PHCl/ Eudragit RL 1:4 (w/w) microcapsule.
Figure 5. SEM of a VHCl/ Eudragit RL 1:4 (w/w) microcapsule.
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established in a qualitative manner. The formulations in 
which the drug/polymer ratio was 1:4 (w/w) produced 
uniform spherical particles that were harder to the touch 
than the ones manufactured at lower drug/polymer 
concentrations. The presence of residual mineral oil 
adsorbed onto the surface of the microcapsules, evident in 
Figure 5, is a consequence of inadequate washing of the 
particles with n-hexane during manufacture. The surface 
of the spheres appeared to become smoother with an 
increase in drug/polymer ratio for PHCl and VHCl.
Liquid paraffin was selected as a bulk or outer phase, 
since PHCl, VHCl, and Eudragit RS/RL are only very slightly 
soluble in liquid paraffin. Acetone has a dielectric constant 
of 20.7 and was therefore chosen as the dispersed or inner 
phase, since solvents with dielectric constants between 10 
and 40 show poor miscibility with liquid paraffin (32, 33). 
Microspheres that were formulated with low concentra-
tions of Eudragit RL and RS were irregular, non-spherical, 
soft, and had poor flowability; therefore, they were not 
considered suitable for analysis.
The dissolution of PHCl and VHCl from the microspheres 
prepared with a 1:4 (w/w) drug/polymer ratio is depicted 
in Figure 8. Examination of the release profiles reveals that 
drug release was generally faster for VHCl and PHCl 
microspheres produced with the RL polymer despite the 
apparent similarity in particle size of the microcapsules. RS 
and RL are copolymers of partial esters of acrylic and 
methacrylic acids containing low amounts of quaternary 
ammonium groups, approximately 5% and 10% for RS and 
RL, respectively (6). The RS polymer is water-insoluble, and 
drug delivery systems prepared from it show pH-indepen-
dent sustained drug release, attributed to the quaternary 
ammonium groups (5). The quaternary ammonium groups 
in the RS and RL chemical structures play an important 
role in controlling drug release because they relate to 
water uptake followed by the swelling of the polymers 
(34). This is most likely because the number of quaternary 
ammonium groups of RS is lower than that of RL, which 
renders RS less permeable.
There was no significant difference between the 
dissolution profiles of PHCl and VHCl for the same polymer, 
since the solubility of each of the drugs is similar. The 
solubility of PHCl is greater than 150 mg/mL (35), and the 
solubility of VHCl is 123 mg/mL (19). 
Figure 6. SEM of a PHCl/ Eudragit RS 1:4 (w/w) microcapsule.
Figure 7. SEM of a VHCl/ Eudragit RS 1:4 (w/w) microcapsule.
Figure 8. Cumulative percent drug released reported as mean ± SD (n = 3).
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The VHCl and PHCl RL microcapsules showed fast 
release; about 60% drug was released within the first hour. 
In the course of our investigation, it was observed that 
microcapsules were released through the wire mesh 
basket. It is important to note that the dissolution behavior 
of granules and powders is greatly influenced by their 
wettability, surface area, and particle size distribution (26), 
and thus release of drugs from microcapsules would be 
affected in a similar manner. In vitro release testing 
constitutes one of the physicochemical parameters 
needed to characterize the product. 
Drug release from microcapsules should theoretically 
be slower as the amount of polymer is increased because 
of an increase in the path length through which the drug 
has to diffuse. 
The total cumulative quantity of drug released at the 
end of the 12-h dissolution test was below 100 % for all 
dosage forms. This may in part be due to the relatively 
slow erosion of the matrix under these test conditions, 
with a resultant slow release of entrapped drug from the 
matrices undergoing testing. 
The curvilinear nature of the cumulative percentage 
drug released versus time plots suggest that drug release 
from the microcapsules did not follow zero-order kinetics. 
This is confirmed by low correlation coefficients obtained 
in all cases when these data were fitted to a zero-order 
model; data are summarized in Table 2. The in vitro 
dissolution study confirmed the Higuchi-order release 
pattern. Dissolution data again fit the Kopcha matrix 
model. However, the mathematical expression that best 
describes drug release from these microcapsules is the 
Makoid–Banakar model, with resultant R2 values greater 
than 0.98. The Korsmeyer–Peppas release exponent, n, is 
about 0.3, which confirms that diffusion is the controlling 
factor in drug release. This was further established as the 
ratio of exponents A/B derived from the Kopcha model is 
greater than 1. The Kopcha model can easily be used to 
help quantify the contribution of diffusion and polymer 
relaxation. As seen from the data in Table 2, the value of A 
is far greater than the value of B, which suggests that drug 
release occurred mainly as a result of Fickian diffusion. The 
mathematical expression that best describes the release is 
the Makoid–Banakar model. When the parameter c of the 
Makoid–Banakar model is equal to zero, this model 
becomes the Korsmeyer–Peppas power law (e-0t = 1). 
A relatively high encapsulation efficiency was observed 
for all microsphere formulations. The encapsulation 
efficiency was greater than 80% for all drug candidates 
investigated, and therefore, it is evident that both the RS 
and RL polymers are potentially useful materials for the 
encapsulation of relatively hydrophilic compounds such 
as PHCl and VHCl.
The good flow properties (HR = 1.2) suggest that the 
microspheres can be easily handled during processing. 
One of the challenges was the formation of gas bubbles 
around the microcapsules that might have affected the 
results of the dissolution test.
CONCLUSION
The solvent-evaporation method using Eudragit 
polymers at optimum levels was effective for the formation 
of PHCl and VHCl microspheres. The PHCl and VHCl 
microcapsules prolonged drug release for about 8 h. 
The Eudragit polymers are water-insoluble materials, 
and therefore, PHCl and VHCl are not miscible with the 
polymer and were preferentially encapsulated. 
The application of USP Apparatus 1 for the assessment 
of the Eudragit microcapsules prepared by solvent 
evaporation was successful, and differences in drug 
release due to formulation effects were observed. This 
data set presents evidence that the two BCS Class I drug 
candidates behave in a similar fashion during formulation 
development and assessment.
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